Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Clin Oncol. 2012 Dec;9(12):672-3. doi: 10.1038/nrclinonc.2012.201. Epub 2012 Nov 20.

Urological cancer. The benefits of intermittent androgen-deprivation therapy.

Author information

1
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

Abstract

The large randomized study by Crook et al. demonstrated that intermittent administration of androgen deprivation therapy should be considered the standard of care when patients with moderate and well-differentiated localized prostate cancer are treated for rising PSA levels after definitive radiotherapy.

PMID:
23165125
DOI:
10.1038/nrclinonc.2012.201
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center